OAB: Current and Emerging Therapies for Optimal Individualized Treatment
Release Date: September 2013
Expiration Date: September 2014
Estimated time to complete the educational activity: 1 hour
This activity is jointly sponsored by Medical Education Resources and Haymarket Medical Education.
Statement of Need: The prevalence of overactive bladder (OAB) suggests that clinicians do not succeed in identifying patients early for optimal individualized treatment. Many patients fail to achieve adequate relief of idiopathic OAB symptoms with current treatments, indicating that physicians frequently may not select therapy tailored to the individual patient to achieve optimal outcomes.
Target Audience: This activity has been designed to meet the educational needs of urologists, urogynecologists, and other health care providers who treat patients with bladder dysfunction.
Educational Objectives: After completing the activity, the participant should be better able to:
- Apply diagnostic and assessment strategies to identify patients with OAB earlier for optimal individualized treatment
- Evaluate current evidence-based treatments and emerging therapies to better select individualized therapy for OAB
Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine (BUSM) and Haymarket Medical Education. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: Boston University School of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest: Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:
|Name of Faculty||Reported Financial Relationship|
|Michael B. Chancellor, MD
Grants/Research Support: Allergan, Inc., Astellas Pharma
US, Inc., Medtronic, Merck & Co., and Pfizer Inc.
Consultant: Allergan, Inc., Cook Medical, Lipella Pharmaceuticals Inc., Merck & Co., and Pfizer Inc.
Stockholder: Cook Medical, Lipella Pharmaceuticals Inc.
|David A. Ginsberg, MD||Grant/Research Support: Allergan, Inc. and Medtronic
Consultant: Allergan, Inc., Medtronic, and Pfizer Inc.
Speakers' Bureau: Allergan, Inc.
The content managers, Jody A. Charnow and Marina Galanakis, at Haymarket Medical Education, and the content manager at Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest.
Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period September 2013 through September 2014, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at www.myCME.com/renalandurologynews, and 4) complete the evaluation form online.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.